午夜插插,噜噜噜影院,啪啪伊人网,欧美熟夫,景甜吻戏视频,男人强操性感蕾丝美女视频在线网站,日本美女跳舞视频

Welcome to chemicalbook!
+1 (818) 612-2111
RFQ
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >Eravacycline Difference phase isomer
Eravacycline Difference phase isomer
  • Eravacycline Difference phase isomer
  • Eravacycline Difference phase isomer
  • Eravacycline Difference phase isomer
  • Eravacycline Difference phase isomer
  • Eravacycline Difference phase isomer

Eravacycline Difference phase isomer NEW

Price Get Latest Price
Package 10mg 50mg 100mg
Min. Order: 10mg
Supply Ability: 1000
Update Time: 2025-06-18

Product Details

Product Name: Eravacycline Difference phase isomer CAS No.: 1431558-65-4
Min. Order: 10mg Purity: 99%+ HPLC
Supply Ability: 1000 Release date: 2025/06/18

Eravacycline Difference phase isomer

Article illustration

Product Information

  • Product Code:E062018

  • English Name:Eravacycline Difference phase isomer

  • English Alias:(4R,4aS,5aR,12aS)-4-(dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-(2-(pyrrolidin-1-yl)acetamido)-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide

  • CAS No.:1431558-65-4

  • Molecular Formula:C??H??FN?O?

  • Molecular Weight:558.56

Advantages

  • High-Purity Isomer Reference Standard:Confirmed by HPLC (≥99.0%), NMR (with chiral shift reagents), HRMS, and X-ray crystallography for stereoconfiguration, suitable for precise analysis of Eravacycline difference phase isomers.

  • Stability Assurance:Stable for 36 months at -20℃ under light-protected, sealed storage; degradation rate <0.2% in methanol-water solution within 6 months.

Applications

  • Quality Control Testing:Used for UPLC-MS/MS detection of difference phase isomers in Eravacycline API and formulations, controlling isomer content to meet ICH Q3A standards (≤0.5%).

  • Process Optimization Research:Monitors difference isomerization side reactions during Eravacycline synthesis, reducing generation by >60% by adjusting hydrogenation temperature (e.g., 10-15℃) and catalyst dosage (e.g., Pd/C).

  • Method Validation:Serves as a standard for developing isomer separation methods, verifying UPLC resolution (≥3.0) and LOD (0.01 ng/mL).

Background Description

Eravacycline, a new-generation tetracycline antibiotic, is used for treating complicated intra-abdominal infections. Difference phase isomers may originate from stereoisomerization of the octahydrotetracene ring during Eravacycline synthesis. The polyhydroxy and chiral centers in its structure may affect drug antibacterial activity and safety. With stricter FDA requirements for antibiotic isomer control, studying such steric impurities is key to ensuring drug quality.

Research Status

  • Detection Technology:UPLC-MS/MS with chiral C18 column (1.7μm) and 0.1% phosphoric acid-water-acetonitrile gradient elution achieves separation within 4 minutes, with LOD of 0.005 ng/mL for high-sensitivity analysis.

  • Formation Mechanism:Formed by epimerization of Eravacycline parent nucleus during hydrogenation; optimizing reaction pressure (e.g., 5-10 atm) and solvent polarity (e.g., ethanol-water system) inhibits side reactions.

  • Safety Evaluation:In vitro antibacterial assays show MIC of 4 μg/mL against E. coli (Eravacycline MIC=0.5 μg/mL), with low toxicity but requiring ≤0.5% limit. Accelerated stability testing is ongoing to monitor isomerization rates under different pH conditions


We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.


This product is intended for laboratory use only!

WhatsAPP: +86 17320513646
E-mail: anna@molcoo.com


NEW IN STOCK!

The Molcoo Laboratory added drug impurity reference standards, including Baricitinib, Piperazine, Benzylpenicillin, Tranilast and multiple N-Nitroso drug impurities! Now available for immediate delivery! 








Company Profile Introduction

1. Drug standards and drug impurity reference substances: provide more than 20,000 kinds of spot impurity reference substances, with sufficient supply and same-day delivery. We have a professional R&D team and comprehensive quality control testing to ensure product quality and reliability. 2. Customized synthesis of impurities and new molecules: Quickly respond to the customized needs of CDE impurities, stably supply impurities that have established quality standards, and provide customized synthesis services for new compounds in the research and development of innovative drugs. 3. Preparation and separation of unknown impurities: With a professional impurity preparation and separation technical team and SFC preparation and separation instruments, we can solve the problems of impurity preparation in complex projects. 4. Process development of new drug intermediates: provide the supply of new drugs and new molecular impurities, process optimization services, as well as the screening and impurity analysis of commercialization routes. 5. Peptide synthesis: Provide customized peptide synthesis services, and cover all kinds of degradation impurities and process impurities generated in the research and development of peptide drugs. At the same time, it provides comprehensive structural confirmation data and customized testing services.

You may like

Recommended supplier

Product name Price   Suppliers Update time
$0.00/10mg
VIP2Y
ShenZhen H&D Pharmaceutical Technology Co., LTD
2025-03-21
$6700.00/100mg
VIP3Y
TargetMol Chemicals Inc.
2025-07-17
$0.00/5mg
VIP1Y
Guangzhou Tosun Pharmaceutical Ltd
2025-01-23
INQUIRY